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Background/aim: Human HIV-1 TAT interactive protein 2 (HTATIP2/TIP30) is a gene that is extensively expressed in human tissues
as well as in tumor tissues. This study aimed to explore the potential role of HTATIP2/TIP30 in contact dermatitis (CD), which is one
of the most common inflammatory cutaneous conditions.
Materials and methods: This cross-sectional study involved adult patients with acute contact dermatitis who were admitted to the
outpatient dermatology clinic of a tertiary hospital and healthy adult volunteers without any cutaneous or systemic diseases. The blood
concentration of HTATIP2/TIP30 was measured using ELISA kits.
Results: The research sample consisted of 31 patients with CD (18 males, 13 females) and 20 healthy control subjects (14 males, 6
females). The mean ages of the patients with CD and healthy volunteers were 37 and 30 years, respectively (p > 0.05). The mean value of
serum HTATIP2/TIP30 levels in patients with CD was 1.65 ng ml–1, which is 0.60 ng ml–1 in the control group (p = 0.02)
Conclusion: In this study, serum levels of HTATIP2/TIP30 were statistically significantly higher in patients with CD when compared to
healthy controls. This outcome may indicate possible role of HTATIP2/TIP30 in the pathogenesis of CD.
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1. Introduction
Contact dermatitis (CD) is an inflammatory skin disease
characterized by pruritus, erythema, vesicles, blisters,
and scales. It can be in the form of acute, subacute, or
chronic dermatitis. Approximately 80% of CD cases
are irritant contact dermatitis (ICD) while 20% are
allergic contact dermatitis (ACD). ICD is the results of
localized, nonimmunological inflammatory reaction.
ACD, unlike ICD, is a type 4 hypersensitivity reaction
to a specific allergen that also results in a series of
inflammatory reactions [1]. Although both forms of
CD may have similar clinical presentations, they can be
differentiated on pathophysiological grounds. Regardless
of the pathophysiological pathway of two different forms,
cutaneous inflammation is essential [2].
Human HIV-1 TAT interactive protein 2 (HTATIP2/
TIP30), which is also called CC3/TIP30, is a pro-apoptotic
protein expressed in different tumors. It has been
described as related to the transcriptional activation area
of HIV-1 Tat, and it is especially cofactor in Tat-activated

transcription [3]. The role of TIP30 in cell death and
tumor suppression is a well-known phenomenon. TIP30
and related factors have been shown to be involved in the
control of gene expression associated with apoptotic and
metastatic processes [4–9].
A wide variety of chronic inflammatory disorders or
autoimmune conditions are associated with an increased
risk of malignancy. The role of chronic inflammation in
cancer development has been a subject of experimental
and epidemiologic studies. It is hypothesized that chronic
infection or persistent inflammation enforces de novo
lymphogenesis and resulted in malignancy. In certain
organs such as the lung and liver, chronic inflammation
related to fibrosis can also be associated with malignant
transformation [10–11]. To the best of our knowledge, no
study has directly investigated the possible relationship
between inflammatory conditions and HTATIP2/TIP30
expression. Almost all the relevant studies have focused
on the role of HTATIP2/TIP30 in cancer pathogenesis.
Uzkeser et al, however, investigated the serum HTATIP2/
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TIP30 levels in patients with rheumatoid arthritis,
ankylosing spondylitis, and sarcoidosis, referring to the
role of inflammation in the cancer pathogenesis. The
authors found that serum HTATIP2/TIP30 levels in
patients with ankylosing spondylitis were higher than
in healthy controls. They concluded that this result may
be associated with low apoptotic activity in patients with
ankylosing spondylitis [12].
In this study, we aimed to investigate serum HTATIP2/
TIP30 levels in patients with contact dermatitis, a
prototypical cutaneous inflammatory condition.
2. Materials and methods
2.1. Design of the study, patient selection, and data
collection
This cross-sectional study involved adult patients with
acute contact dermatitis who were admitted to the
outpatient dermatology clinic of a tertiary hospital
between January 2014 and August 2015 and healthy adult
volunteers without any cutaneous or systemic diseases.
Patients with a cutaneous condition other than CD or a
systemic disease were excluded. Subacute or chronic cases
of CD were also rule out. The diagnosis of CD was made
by the expert opinion of the author based on the clinical
characteristics and detailed history. The control group
consisted of age- and sex-matched healthy volunteers. All
patients were newly diagnosed, and none of them received
topical or oral corticosteroids before the diagnosis. After at
least 8 h of fasting, 5 cc peripheral venous blood samples
were collected into two blood collection tubes from all
participants. Serum samples of CD and healthy controls
were obtained after centrifugation and stored at –80 oC
until the analysis date. The serum HTATIP2/TIP30 levels
were tested using a HTATIP2/TIP30 enzyme-linked
immunosorbent assay (ELISA) kit (Cusabio Biotech Co.,
Ltd. Catalog No: CSB-E14917H) in accordance with the
manufacturer’s instructions.
2.2. Statistical analysis
Computerized statistics software (SPSS, Inc., Chicago,
IL, USA) was used for statistical analysis. Descriptive
data were given as mean ± standard deviation, number,
or percentage. Unpaired Student’s t-test was used for
comparisons of HTATIP2/TIP30 levels between the

groups. The statistically significant level was set at p < 0.05.
The actual power of the study was found to be 0.78. Power
analysis was calculated using the G-Power (G*Power
Version 3.1.9.6; Universitat Kiel, Germany) package
program.
3. Results
The research sample consisted of 31 patients with CD (18
males, 13 females) and 20 healthy control subjects (14
males, 6 females). The mean ages of the patients with CD
and healthy volunteers were 37 (range 20–62 years) and
30 years (range 18–44 years), respectively. There were no
differences between the groups in terms of age or sex (p>
0.05) (Table 1). The mean value of serum HTATIP2/TIP30
levels was significantly higher in patients group (1.654
± 1.82 ng ml–1) compared to those of the controls (0.603
±0.21 ng ml–1). (Table 2, Figure 1). In addition, HTATIP2/
TIP30 levels were higher in men than women both in the
control (p < 0.05) and patient groups (p < 0.05) (Figure 2).
4. Discussion
A limited number of studies investigated the role of
HTATIP2/TIP 30 expression in various diseases [13]. In
this study, we found that the levels of HTATIP2/TIP30 were
significantly higher in patients with CD when compared to
healthy subjects.
Contact dermatitis (CD) is a worldwide, frequent
disease, which is responsible for about 10% of the visits to
dermatology offices. CD expresses a group of cutaneous
diseases caused by contact with allergens or irritants. It is
characterized by different stages of an eczematous eruption.
Irritant contact dermatitis (ICD) and allergic contact
dermatitis (ACD) are considered as the two subgroups of

Table 1. Some demographics properties in patient and control
groups.
Parameters

Control

CD

Number

20

31

Age (range)

30.35 (18–44)

36.96 (20–62)

Sex

14 M/6 F

18 M/13F

Table 2. Serum HTATIP2/TIP30 levels in patient and control groups.
Groups

Number

Mean, ng ml

Control

20(14M/6F)

Patient

31(18M/13F)

–1

S.D.

p

max d

min d

0.603(0.673M/0.533F)

0.214

0.02*

1.09

0.36

1.654(1.724M/1.584F)

1.828

9.32

0.37

*p < 0.05 significant level (unpaired t-test). M: Male, F: Female, SD: Standard deviation.
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HTATIP2/TIP30(ngml^-1)

2.00
1.80
1.60
1.40
1.20
1.00
1.654

.80
.60
.40

.603

.20
.00

CD

Control

Figure 1. HTATIP2/TIP30 in blood of patients with CD and control group.
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HTATIP2/TIP30(ngml^-1)
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1.00
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.60
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.673
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Figure 2. The paired t-test showed a significant difference between men and women
in the control and patient groups in terms of average HTATIP2/TIP30 and evaluated
using Student’s t test (t = 0.45, p < 0.05). Different letters indicate signiﬁcant differences
between means.

the entity [14]. ACD is a type 4 or delayed hypersensitivity
reaction. It occurs after exposure to an allergen, which
activates T helper 1 cells in a previously sensitized
individual. ICD, unlike ACD, is a nonimmunologic
inflammatory reaction that can be seen in anyone who has
been exposed to sufficient duration and number of irritant
agents causing direct epidermal keratinocyte damage
[15–17]. Although the causes of these two conditions may
differ, both have quite similar clinical, histological, and
molecular features.

Both innate and acquired immunity play roles in the
immune response against cancer [18]. The pathology of
inflammation comprises two main events that consisted
of vascular and cellular events. During vascular events,
interstitial edema occurs because of vascular leakage of
exudate due to vasodilatation and increased vascular
permeability. This is the sign of a “tumor” of inflammation.
The most impressive functional alteration among
cellular events is the migration of leukocytes to the area
and secretion of their products into the medium [19].
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HTATIP2/TIP30 is actually a normal cellular protein
described as a tumor suppressor [20–21]. It is known that
its secretion is augmented by heat shock proteins, stress,
certain viruses (i.e. EBV, retrovirus), TGF-β, and aging
[21]. Tumor suppressor activity of HTATIP2/TIP 30 is
associated with suppressing a pro-inflammatory cytokine
called osteopontin (OPN), which has an important role
in cellular immunity and existed in T helper 17 (IL-17
producing T helper cells) along with blockage of nuclear
pores and induction of apoptosis [22]. It has been shown
that HTATIP2/TIP30 levels are decreased in variantsmall cell lung carcinoma (V-SCLC), classic-SCLC,
neuroblastoma (NB), colon cancer, melanoma, prostate
cancer, and hepatocellular carcinoma (HCC) [23–24].
Liu et al. reported that the loss of function of TIP30 has
been linked to metastasis in nonsmall cell lung cancer
(NSCLC). In another study, researchers demonstrated
that the absence of HTATIP2 expression in A549 human
NSCLC cells resulted in accelerated tumor growth despite
stalled tumor neovascularization and reduced tumor
oxygenation, and lowered tumor sensitivity to sorafenib
treatment.
Engkilde et al. reported that contact allergy was found
to be associated with four different cancer subtypes. Most
of the relationships were inverted, which may support the
immune surveillance hypothesis. They found a meaningful
and inverse connection between contact allergy and breast
cancer and non-melanoma skin cancer, respectively, as
well as a meaningful and positive connection between
contact allergy and bladder cancer [25]. In patients with
cancer, an immune response occurs against the tumor
cell. However, this immune response is not sufficient for
eradicating malignant cells or preventing metastasis. In
these patients, foreign microorganisms such as bacteria or
viruses are perceived as a signal of danger and generate
a very strong immune response, whereas tumor cells are
perceived as self-cells and a weaker immune response
develops. In patients with cancer, a high amount of
CD4+, CD25+ cells are detected in the circulation and
around tumoral tissue. Not only tumor-related antigenspecific T cells but also nonspecific T cells, natural killer
cells, and macrophages play role in the development of
immune response against tumoral tissue [26]. Zhang
et al. reported that interventional therapy for primary

HCC has good short-term efficacy. This therapy reduces
the levels of serum HTATIP2/TIP30, B7-H4, AFP, and
inflammation-related indexes [27]. Certain chronic
inflammatory disorders or autoimmune conditions are
associated with an increased risk of malignancy. The role
of chronic inflammation in cancer development has been a
subject of experimental and epidemiologic studies [11,28].
Consequently, both innate and acquired immunity play
role in the pathogenesis of the malignant diseases as well
as that of CD. Although several studies have shown the
role of HTATIP2/TIP30 in malignant diseases, there is no
study assessing the potential role of HTATIP2/TIP30 in
CD.
Our study has several limitations that need to be
addressed. The first one is the relatively small number
of participants. Second, the cross-sectional design of the
study did not make it possible to remeasure HTATIP2/
TIP30 levels after cutaneous inflammation had resolved.
Third, it is hard to draw a robust conclusion on the
relationship between HTATIP2/TIP30 and contact
dermatitis, since tissue expression of HTATIP2/TIP30 and
detailed immunological evaluations were not made.
In this study, we found significantly higher serum
HTATIP2/TIP30 levels in patients with CD when
compared to healthy controls. However, prospective
studies with tissue expression analysis are warranted to
demonstrate the potential role of HTATIP2/TIP30 in
inflammatory events.
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